Skip to content
A Landmark Trial (without an FDA approval) episode artwork

Apr 29, 2021 13 min

A Landmark Trial (without an FDA approval)

from OncoPharm Hosted by John Bossaer

An abbreviated edition of our Landmarks in #OncoPharm series returns to discuss weekly cisplatin + radiotherapy for locally advanced cervical cancer. As a bonus, we cover a new study establishing FOLFOX as the standard-of-care for 2nd line treatment of metastatic biliary cancer. All of this is discussed against the backdrop of the relative importance (or lack thereof?) of obtaining an approved indication.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

A Landmark Trial (without an FDA approval)

0:00 13:24

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of OncoPharm?

This episode is 13 minutes long.

When was this OncoPharm episode published?

This episode was published on April 29, 2021.

Can I download this OncoPharm episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.